| Year |
Citation |
Score |
| 2023 |
Elmarsafawi AG, Hesterberg RS, Fernandez MR, Yang C, Darville LN, Liu M, Koomen JM, Phanstiel Iv O, Atkins R, Mullinax JE, Pilon-Thomas SA, Locke FL, Epling-Burnette PK, Cleveland JL. Modulating the polyamine-hypusine axis controls generation of CD8+ tissue resident memory T cells. Jci Insight. PMID 37581943 DOI: 10.1172/jci.insight.169308 |
0.37 |
|
| 2023 |
Mhibik M, Gaglione EM, Eik D, Herrick J, Le J, Ahn IE, Chiu C, Wielgos-Bonvallet M, Hiemstra IH, Breij EC, Chen J, Reilly EB, Epling-Burnette PK, Szafer Glusman E, Sun C, et al. Cytotoxicity of the CD3xCD20 bispecific antibody epcoritamab in CLL is increased by concurrent BTK or Bcl-2 targeting. Blood Advances. PMID 37219524 DOI: 10.1182/bloodadvances.2022009517 |
0.387 |
|
| 2020 |
Hesterberg RS, Beatty MS, Han Y, Fernandez MR, Akuffo AA, Goodheart WE, Yang C, Chang S, Colin C, Alontaga AY, McDaniel J, Mailloux AW, Billington JMR, Yue L, Russell S, ... ... Epling-Burnette PK, et al. Cereblon Harnesses Myc-Dependent Bioenergetics and Activity of CD8+ T lymphocytes. Blood. PMID 32403132 DOI: 10.1182/Blood.2019003257 |
0.726 |
|
| 2020 |
Zhang Q, Haider M, Al Ali NH, Lancet JE, Epling-Burnette PK, List AF, Padron E, Komrokji RS. SF3B1 Mutations Negatively Predict for Response to Immunosuppressive Therapy in Myelodysplastic Syndromes. Clinical Lymphoma, Myeloma & Leukemia. PMID 32179032 DOI: 10.1016/J.Clml.2019.12.023 |
0.328 |
|
| 2020 |
Rollison DE, Fenske NA, Cherpelis B, Messina JL, Zhao Y, Amorrortu RP, Hesterberg R, Epling-Burnette PK. Abstract 3492: Circulating immunosuppressive regulatory T cells and risk of incident cutaneous squamous cell carcinoma Epidemiology. 80: 3492-3492. DOI: 10.1158/1538-7445.Am2020-3492 |
0.381 |
|
| 2019 |
Yue L, Sharma V, Horvat NP, Akuffo AA, Beatty MS, Murdun C, Colin C, Billington J, Goodheart WE, Sahakian E, Zhang L, Powers JJ, Amin NE, Lambert-Showers QT, Darville LN, ... ... Epling-Burnette PK, et al. HDAC11 Deficiency or Inhibition Disrupts Oncogene-Induced Stress Hematopoiesis in Myeloproliferative Neoplasms. Blood. PMID 31750881 DOI: 10.1182/Blood.2019895326 |
0.366 |
|
| 2019 |
Mazzacurati L, Collins RJ, Pandey G, Lambert-Showers QT, Amin NE, Zhang L, Stubbs MC, Epling-Burnette PK, Koblish HK, Reuther GW. The pan-PIM inhibitor INCB053914 displays potent synergy in combination with ruxolitinib in models of MPN. Blood Advances. 3: 3503-3514. PMID 31725895 DOI: 10.1182/Bloodadvances.2019000260 |
0.347 |
|
| 2019 |
Sekeres MA, Gore SD, Stablein DM, DiFronzo N, Abel GA, DeZern AE, Troy JD, Rollison DE, Thomas JW, Waclawiw MA, Liu JJ, Al Baghdadi T, Walter MJ, Bejar R, Gorak EJ, ... ... Epling-Burnette PK, et al. The National MDS Natural History Study: design of an integrated data and sample biorepository to promote research studies in myelodysplastic syndromes. Leukemia & Lymphoma. 1-11. PMID 31111762 DOI: 10.1080/10428194.2019.1616186 |
0.322 |
|
| 2019 |
Park DS, Akuffo AA, Muench DE, Grimes HL, Epling-Burnette PK, Maini PK, Anderson ARA, Bonsall MB. Clonal hematopoiesis of indeterminate potential and its impact on patient trajectories after stem cell transplantation. Plos Computational Biology. 15: e1006913. PMID 31026273 DOI: 10.1371/Journal.Pcbi.1006913 |
0.328 |
|
| 2019 |
Pandey G, Horvat N, Amin NE, Akuffo AA, Colin C, Epling-Burnette PK, Reuther GW. RMC-4550, an Allosteric Inhibitor of SHP2, Displays Therapeutic Efficacy in Pre-Clinical Models of Myeloproliferative Neoplasms Blood. 134: 4198-4198. DOI: 10.1182/Blood-2019-128937 |
0.452 |
|
| 2019 |
Balasis ME, Vedder A, Sun L, Quintana A, Dhawan A, Newman H, Merlevede J, McGraw K, Kruer T, Ben-Crentsil N, Painter JS, Droin N, Cluzeau T, Letson C, Wei S, ... ... Epling-Burnette PK, et al. Depletion of the Long Non-Coding RNA MALAT1 primes Chronic Myelomonocytic Leukemia (CMML) for Differentiation Therapy with All-Trans retinoic Acid (ATRA) through the Transcription Factor CREB Blood. 134: 1692-1692. DOI: 10.1182/Blood-2019-128573 |
0.409 |
|
| 2019 |
Letson C, Vedder A, Quintana A, Liu P, Reid B, Balasis ME, Newman H, Kruer T, Almada LL, Zhang G, Fernandez-Zapico M, Patnaik MM, Lancet JE, Komrokji RS, Epling-Burnette P, et al. Bromodomain and Extra Terminal Domain (BET) Inhibitors Sensitize Chronic Myelomonocytic Leukemia (CMML) to PIM Inhibition Via Downregulation of Mir-33a Blood. 134: 4220-4220. DOI: 10.1182/Blood-2019-128165 |
0.355 |
|
| 2019 |
Sharma V, Yue L, Horvat NP, Christodoulidou A, Akuffo AA, Beatty M, Murdun C, Billington J, Goodheart WE, Sahakian E, Zhang L, Powers JJ, Amin NE, Lambert-Showers QT, Darville L, ... ... Epling-Burnette PK, et al. Selective Targeting of Histone Deacetylase 11 Disables Metabolism of Myeloproliferative Neoplasms Blood. 134: 474-474. DOI: 10.1182/Blood-2019-127235 |
0.35 |
|
| 2019 |
Goll JB, Lindsley RC, Hooper WF, Bejar R, Walker J, Fulton R, Abel GA, Al Baghdadi T, Deeg HJ, DeZern AE, Ebert B, Epling-Burnette P, Foran JM, Gorak EJ, Gore SD, et al. Clonal Cytopenias of Undetermined Significance Are Common in Cytopenic Adults Evaluated for MDS in the National MDS Study Blood. 134: 4271-4271. DOI: 10.1182/Blood-2019-126978 |
0.342 |
|
| 2018 |
Komrokji RS, Wei S, Mailloux AW, Zhang L, Padron E, Sallman D, Lancet JE, Tinsley S, Nardelli LA, Pinilla-Ibarz J, Epling-Burnette PK, List AF. A Phase II Study to Determine the Safety and Efficacy of the Oral Inhibitor of Indoleamine 2,3-Dioxygenase (IDO) Enzyme INCB024360 in Patients with Myelodysplastic Syndromes. Clinical Lymphoma, Myeloma & Leukemia. PMID 30713125 DOI: 10.1016/J.Clml.2018.12.005 |
0.382 |
|
| 2018 |
Hesterberg RS, Amorrortu RP, Zhao Y, Hampras S, Akuffo AA, Fenske N, Cherpelis B, Balliu J, Vijayan L, Epling-Burnette PK, Rollison DE. T Regulatory Cell Subpopulations Associated with Recent Ultraviolet Radiation Exposure in a Skin Cancer Screening Cohort. Journal of Immunology (Baltimore, Md. : 1950). 201: 3269-3281. PMID 30389774 DOI: 10.4049/Jimmunol.1800940 |
0.402 |
|
| 2018 |
Shastri A, Choudhary G, Teixeira M, Gordon-Mitchell S, Ramachandra N, Bernard L, Bhattacharyya S, Lopez R, Pradhan K, Giricz O, Ravipati G, Wong LF, Cole S, Bhagat TD, Feld J, ... ... Epling-Burnette PK, et al. Antisense STAT3 inhibitor decreases viability of myelodysplastic and leukemic stem cells. The Journal of Clinical Investigation. PMID 30252677 DOI: 10.1172/Jci120156 |
0.42 |
|
| 2018 |
Hesterberg RS, Cleveland JL, Epling-Burnette PK. Role of Polyamines in Immune Cell Functions. Medical Sciences (Basel, Switzerland). 6. PMID 29517999 DOI: 10.3390/Medsci6010022 |
0.374 |
|
| 2018 |
Akuffo AA, Alontaga AY, Metcalf R, Beatty MS, Becker A, McDaniel JM, Hesterberg RS, Goodheart WE, Gunawan S, Ayaz M, Yang Y, Karim MR, Orobello ME, Daniel K, Guida W, ... ... Epling-Burnette PK, et al. Ligand-mediated protein degradation reveals functional conservation among sequence variants of the CUL4-type E3 ligase substrate receptor cereblon. The Journal of Biological Chemistry. PMID 29449372 DOI: 10.1074/Jbc.M117.816868 |
0.663 |
|
| 2017 |
Duong VH, Padron E, Al Ali NH, Lancet JE, Hall J, Kwok B, Zhang L, Epling-Burnette PK, List AF, Komrokji RS. The prognostic value of circulating myeloblasts in patients with myelodysplastic syndromes. Annals of Hematology. PMID 29167940 DOI: 10.1007/S00277-017-3186-4 |
0.354 |
|
| 2017 |
Zhang Q, Ball MC, Zhao Y, Balasis M, Letson C, Vedder A, List AF, Epling-Burnette PK, Komrokji RS, Padron E. Intrapatient functional clonality deconvoluted by coupling intracellular flow cytometry and next-generation sequencing in human leukemia. Leukemia. PMID 28694526 DOI: 10.1038/Leu.2017.184 |
0.348 |
|
| 2017 |
Yue L, Bartenstein M, Zhao W, Ho WT, Han Y, Murdun C, Mailloux AW, Zhang L, Wang X, Budhathoki A, Pradhan K, Rapaport F, Wang H, Shao Z, Ren X, ... ... Epling-Burnette PK, et al. Efficacy of ALK5 inhibition in myelofibrosis. Jci Insight. 2: e90932. PMID 28405618 DOI: 10.1172/Jci.Insight.90932 |
0.32 |
|
| 2017 |
Han Y, Yue L, Wei M, Ren X, Shao Z, Zhang L, Levine RL, Epling-Burnette PK. Mesenchymal Cell Reprogramming in Experimental MPLW515L Mouse Model of Myelofibrosis. Plos One. 12: e0166014. PMID 28135282 DOI: 10.1371/Journal.Pone.0166014 |
0.353 |
|
| 2017 |
Bartenstein M, Yue L, Zhao W, Ho WT, Murdun C, Mailloux AW, Zhang L, Budhakoti A, Pradhan K, Rapaport F, Wang H, Shao Z, Steidl U, Levine RL, Zhao ZJ, ... ... Epling-Burnette PK, et al. Abstract 954: TGF-ß signaling inhibition counteracts myelofibrosis in MPN Cancer Research. 77: 954-954. DOI: 10.1158/1538-7445.Am2017-954 |
0.338 |
|
| 2016 |
Dong W, Wu L, Sun H, Ren X, Epling-Burnette PK, Yang L. MDS shows a higher expression of hTERT and alternative splice variants in unactivated T-cells. Oncotarget. PMID 27655690 DOI: 10.18632/Oncotarget.12115 |
0.403 |
|
| 2016 |
Haider M, Al Ali N, Padron E, Epling-Burnette P, Lancet J, List A, Komrokji R. Immunosuppressive Therapy: Exploring an Underutilized Treatment Option for Myelodysplastic Syndrome. Clinical Lymphoma, Myeloma & Leukemia. 16: S44-8. PMID 27521323 DOI: 10.1016/J.Clml.2016.02.017 |
0.303 |
|
| 2016 |
Dong W, Ding T, Wu L, Ren X, Epling-Burnette PK, Yang L. Effect of IL-7 and IL-15 on T cell phenotype in myelodysplastic syndromes. Oncotarget. PMID 27036031 DOI: 10.18632/Oncotarget.8459 |
0.437 |
|
| 2016 |
Komrokji RS, Kulasekararaj A, Al Ali NH, Kordasti S, Bart-Smith E, Craig BM, Padron E, Zhang L, Lancet JE, Pinilla-Ibarz J, List AF, Mufti GJ, Epling-Burnette PK. Autoimmune Diseases and Myelodysplastic Syndromes. American Journal of Hematology. PMID 26875020 DOI: 10.1002/Ajh.24333 |
0.357 |
|
| 2016 |
Mcgraw KL, Nguyen J, Alali N, Song J, Sallman D, Padron E, Lancet JE, Qin D, Epling-Burnette P, Moscinski LC, Komrokji RS, List AF, Zhang L. EZH2 Protein Expression Is Decreased in MDS and MDS/MPN and Correlated with EZH2 Mutation Status, Chromosomal 7 Abnormalities and Clinical Outcome Blood. 128: 4305-4305. DOI: 10.1182/Blood.V128.22.4305.4305 |
0.349 |
|
| 2016 |
Roe C, Ali N, Epling-Burnette PK, Bennett J, Padron E, Sallman D, Sokol L, Lancet J, List A, Komrokji R. T-Cell Large Granular Lymphocyte Proliferation (LGL) in Patients with Myelodysplastic Syndromes (MDS): Not an Innocent Bystander? Clinical Lymphoma, Myeloma & Leukemia. 16. DOI: 10.1016/J.Clml.2016.07.125 |
0.44 |
|
| 2015 |
McGraw KL, Cluzeau T, Sallman DA, Basiorka AA, Irvine BA, Zhang L, Epling-Burnette PK, Rollison DE, Mallo M, Sokol L, Solé F, Maciejewski J, List AF. TP53 and MDM2 single nucleotide polymorphisms influence survival in non-del(5q) myelodysplastic syndromes. Oncotarget. PMID 26416416 DOI: 10.18632/Oncotarget.5255 |
0.301 |
|
| 2015 |
Yang L, Qian Y, Eksioglu E, Epling-Burnette PK, Wei S. The inflammatory microenvironment in MDS. Cellular and Molecular Life Sciences : Cmls. 72: 1959-66. PMID 25662443 DOI: 10.1007/S00018-015-1846-X |
0.405 |
|
| 2015 |
Peker D, Padron E, Bennett JM, Zhang X, Horna P, Epling-Burnette PK, Lancet JE, Pinilla-Ibarz J, Moscinski L, List AF, Komrokji RS, Zhang L. A close association of autoimmune-mediated processes and autoimmune disorders with chronic myelomonocytic leukemia: observation from a single institution. Acta Haematologica. 133: 249-56. PMID 25413011 DOI: 10.1159/000365877 |
0.349 |
|
| 2015 |
Yue L, Han Y, Zhang L, Wei S, Ren X, Shao Z, Epling-Burnette PK. Mesenchymal Cell Associated Fibrosis in Experimental mplW515L Mouse Model of Myelofibrosis Blood. 126: 604-604. DOI: 10.1182/Blood.V126.23.604.604 |
0.368 |
|
| 2015 |
Yue L, Bartenstein M, Zhao W, Ho W, Zhang L, Rapaport F, Levine RL, Shao Z, Zhao ZJ, Verma A, Epling-Burnette PK. Preclinical Efficacy of TGF-Beta Receptor I Kinase Inhibitor, Galunisertib, in Myelofibrosis Blood. 126: 603-603. DOI: 10.1182/Blood.V126.23.603.603 |
0.339 |
|
| 2015 |
Hesterberg RS, Epling-Burnette PK. Genetic Ablation of Cereblon (CRBN) Increases Long-Lived Memory T Cells Blood. 126: 3440-3440. DOI: 10.1182/Blood.V126.23.3440.3440 |
0.455 |
|
| 2015 |
Beatty MS, Hesterberg RS, Han Y, Padron E, Mailloux AW, Yoder S, Rajadhyaksha AM, List AF, Epling-Burnette PK. Cereblon Deficiency Leads to Alteration in c-Myc Regulated Genes, Increased Glucose Uptake and Resistance to JQ1 Bromodomain Inhibition Blood. 126: 286-286. DOI: 10.1182/Blood.V126.23.286.286 |
0.448 |
|
| 2015 |
Balasis ME, Merelvede J, Kunigal S, Ren X, Ma Y, Zhang Q, Painter J, Droin NM, Johnson J, Yoder S, Komrokji RS, Zhang L, Wei S, Haferlach T, MacLeod R, ... ... Epling-Burnette PK, et al. Molecular Characterization of SRSF2 Mutation Identifies a Clinically Relevant Lncrna (MALAT1) in Chronic Myelomonocytic Leukemia (CMML) Blood. 126: 1641-1641. DOI: 10.1182/Blood.V126.23.1641.1641 |
0.387 |
|
| 2015 |
Haider M, Padron E, Epling-Burnette P, Lancet J, List A, Komrokji R. Immunosuppressive Therapy: Exploring An Underutilized Treatment Option For MDS Clinical Lymphoma, Myeloma & Leukemia. 15. DOI: 10.1016/J.Clml.2015.07.100 |
0.312 |
|
| 2014 |
Gleason MK, Ross JA, Warlick ED, Lund TC, Verneris MR, Wiernik A, Spellman S, Haagenson MD, Lenvik AJ, Litzow MR, Epling-Burnette PK, Blazar BR, Weiner LM, Weisdorf DJ, Vallera DA, et al. CD16xCD33 bispecific killer cell engager (BiKE) activates NK cells against primary MDS and MDSC CD33+ targets. Blood. 123: 3016-26. PMID 24652987 DOI: 10.1182/Blood-2013-10-533398 |
0.47 |
|
| 2014 |
Komrokji RS, Mailloux AW, Chen DT, Sekeres MA, Paquette R, Fulp WJ, Sugimori C, Paleveda-Pena J, Maciejewski JP, List AF, Epling-Burnette PK. A phase II multicenter rabbit anti-thymocyte globulin trial in patients with myelodysplastic syndromes identifying a novel model for response prediction. Haematologica. 99: 1176-83. PMID 24488560 DOI: 10.3324/Haematol.2012.083345 |
0.45 |
|
| 2014 |
Mailloux AW, Epling-Burnette PK. Abstract 1670: Collagen matrix deposition by hepatic stellate cells protects hepatocellular carcinoma from NK-mediated cytotoxicity Cancer Research. 74: 1670-1670. DOI: 10.1158/1538-7445.Am2014-1670 |
0.324 |
|
| 2013 |
Chen X, Eksioglu EA, Zhou J, Zhang L, Djeu J, Fortenbery N, Epling-Burnette P, Van Bijnen S, Dolstra H, Cannon J, Youn JI, Donatelli SS, Qin D, De Witte T, Tao J, et al. Induction of myelodysplasia by myeloid-derived suppressor cells. The Journal of Clinical Investigation. 123: 4595-611. PMID 24216507 DOI: 10.1172/Jci67580 |
0.475 |
|
| 2013 |
Mailloux AW, Zhang L, Moscinski L, Bennett JM, Yang L, Yoder SJ, Bloom G, Wei C, Wei S, Sokol L, Loughran TP, Epling-Burnette PK. Fibrosis and subsequent cytopenias are associated with basic fibroblast growth factor-deficient pluripotent mesenchymal stromal cells in large granular lymphocyte leukemia. Journal of Immunology (Baltimore, Md. : 1950). 191: 3578-93. PMID 24014875 DOI: 10.4049/Jimmunol.1203424 |
0.418 |
|
| 2013 |
Padron E, Painter JS, Kunigal S, Mailloux AW, McGraw K, McDaniel JM, Kim E, Bebbington C, Baer M, Yarranton G, Lancet J, Komrokji RS, Abdel-Wahab O, List AF, Epling-Burnette PK. GM-CSF-dependent pSTAT5 sensitivity is a feature with therapeutic potential in chronic myelomonocytic leukemia. Blood. 121: 5068-77. PMID 23632888 DOI: 10.1182/Blood-2012-10-460170 |
0.705 |
|
| 2013 |
Mishra A, Corrales-Yepez M, Ali NA, Kharfan-Dabaja M, Padron E, Zhang L, Epling-Burnette PK, Pinilla-Ibarz J, Lancet JE, List AF, Komrokji RS. Validation of the revised International Prognostic Scoring System in treated patients with myelodysplastic syndromes. American Journal of Hematology. 88: 566-70. PMID 23605934 DOI: 10.1002/Ajh.23454 |
0.328 |
|
| 2013 |
Mailloux AW, Epling-Burnette PK. Effector memory regulatory T-cell expansion marks a pivotal point of immune escape in myelodysplastic syndromes. Oncoimmunology. 2: e22654. PMID 23524348 DOI: 10.4161/Onci.22654 |
0.402 |
|
| 2013 |
Duong VH, Lancet JE, Alrawi E, Al-Ali NH, Perkins J, Field T, Epling-Burnette PK, Zhang L, List AF, Komrokji RS. Outcome of azacitidine treatment in patients with therapy-related myeloid neoplasms with assessment of prognostic risk stratification models. Leukemia Research. 37: 510-5. PMID 23332452 DOI: 10.1016/J.Leukres.2012.12.012 |
0.363 |
|
| 2013 |
Yang L, Mailloux A, Rollison DE, Painter JS, Maciejewski J, Paquette RL, Loughran TP, McGraw K, Makishima H, Radhakrishnan R, Wei S, Ren X, Komrokji R, List AF, Epling-Burnette PK. Naive T-cells in myelodysplastic syndrome display intrinsic human telomerase reverse transcriptase (hTERT) deficiency. Leukemia. 27: 897-906. PMID 23072779 DOI: 10.1038/Leu.2012.300 |
0.459 |
|
| 2013 |
Wei S, Chen X, McGraw K, Zhang L, Komrokji R, Clark J, Caceres G, Billingsley D, Sokol L, Lancet J, Fortenbery N, Zhou J, Eksioglu EA, Sallman D, Wang H, ... Epling-Burnette PK, et al. Lenalidomide promotes p53 degradation by inhibiting MDM2 auto-ubiquitination in myelodysplastic syndrome with chromosome 5q deletion. Oncogene. 32: 1110-20. PMID 22525275 DOI: 10.1038/Onc.2012.139 |
0.324 |
|
| 2013 |
Epling-Burnette PK, Han Y, Mailloux AW, Zhang L, McDaniel JM, Anjali R, Wei S, David R, Neeson P, Komrokji RS, List A. Novel Predictor Of Lenalidomide Response In Non-del5q MDS Reveals Linkage To Molecular Mechanism: First Characterization Of T-Cell Function In Cereblon Homozygous Deficient Mice Blood. 122: 748-748. DOI: 10.1182/Blood.V122.21.748.748 |
0.749 |
|
| 2013 |
Komrokji RS, Kulasekararaj AG, Ali NHA, Kordasti SY, Bart-smith E, Benjamin C, Padron E, Zhang L, Lancet JE, List A, Mufti GJ, Epling-Burnette PK. Characteristics and Outcome Of Myelodysplastic Syndromes (MDS) Patients With Autoimmune Diseases Blood. 122: 746-746. DOI: 10.1182/Blood.V122.21.746.746 |
0.371 |
|
| 2013 |
Kunigal S, Teer J, Painter J, Yoder SJ, Kim E, Zhang L, Lancet JE, Komrokji RS, Abdel-Wahab O, List A, Epling-Burnette PK, Padron E. JAK2 Dependent GM-CSF Signaling Triggers SRSF2 Phosphorylation: A Potential Cause Of Mutation-Independent RNA Splicing Aberrancy In CMML Blood. 122: 2772-2772. DOI: 10.1182/Blood.V122.21.2772.2772 |
0.344 |
|
| 2013 |
Padron E, Kunigal S, Ren X, Painter JS, Metcalf R, Johnson J, Zhang L, Lancet JE, Komrokji RS, Daniels K, List A, Epling-Burnette PK. SRSF2 Mutations Impair Nuclear Aggregation and Represent a Novel Mechanism Of Spliceosomal Dysregulation In CMML Blood. 122: 260-260. DOI: 10.1182/Blood.V122.21.260.260 |
0.312 |
|
| 2013 |
Mailloux AW, Painter J, Padron E, Loughran TP, Epling-Burnette PK. Common γ Chain (γc) Cytokine Hypersensitivity Leads To T-Cell Homeostatic Deregulation Independent Of STAT3 Mutation In Large Granular Lymphocyte Leukemia Blood. 122: 1628-1628. DOI: 10.1182/Blood.V122.21.1628.1628 |
0.454 |
|
| 2013 |
Epling-Burnette PK, Mailloux AW, Zhang L, Moscinski LC, Wei S, Yoder SJ, Sokol L, Thomas LP. Pluripotent Fibrosis Initiating Mesenchymal Stromal Cell Linked To Cytopenias In LGL Leukemia Through Genetic Reprogramming Blood. 122: 1218-1218. DOI: 10.1182/Blood.V122.21.1218.1218 |
0.414 |
|
| 2013 |
Han Y, Rajadhyaksha AM, Mailloux AW, Painter J, McDaniel JM, Zhang L, Epling-Burnette PK. Characterization Of RING Finger E3-Ubiquitin Ligase Cereblon In Hematopoietic Regulation Blood. 122: 1207-1207. DOI: 10.1182/Blood.V122.21.1207.1207 |
0.734 |
|
| 2012 |
Epling-Burnette PK, McDaniel J, Wei S, List AF. Emerging immunosuppressive drugs in myelodysplastic syndromes. Expert Opinion On Emerging Drugs. 17: 519-41. PMID 23163589 DOI: 10.1517/14728214.2012.736487 |
0.684 |
|
| 2012 |
McDaniel JM, Pinilla-Ibarz J, Epling-Burnette PK. Molecular action of lenalidomide in lymphocytes and hematologic malignancies. Advances in Hematology. 2012: 513702. PMID 22888354 DOI: 10.1155/2012/513702 |
0.706 |
|
| 2012 |
Mailloux AW, Sugimori C, Komrokji RS, Yang L, Maciejewski JP, Sekeres MA, Paquette R, Loughran TP, List AF, Epling-Burnette PK. Expansion of effector memory regulatory T cells represents a novel prognostic factor in lower risk myelodysplastic syndrome. Journal of Immunology (Baltimore, Md. : 1950). 189: 3198-208. PMID 22875800 DOI: 10.4049/Jimmunol.1200602 |
0.495 |
|
| 2012 |
Sugimori C, Padron E, Caceres G, Shain K, Sokol L, Zhang L, Tiu R, O'Keefe CL, Afable M, Clemente M, Lee JM, Maciejewski JP, List AF, Epling-Burnette PK, Araten DJ. Paroxysmal nocturnal hemoglobinuria and concurrent JAK2(V617F) mutation. Blood Cancer Journal. 2: e63. PMID 22829258 DOI: 10.1038/Bcj.2012.7 |
0.393 |
|
| 2012 |
Kriss CL, Pinilla-Ibarz JA, Mailloux AW, Powers JJ, Tang CH, Kang CW, Zanesi N, Epling-Burnette PK, Sotomayor EM, Croce CM, Del Valle JR, Hu CC. Overexpression of TCL1 activates the endoplasmic reticulum stress response: a novel mechanism of leukemic progression in mice. Blood. 120: 1027-38. PMID 22692508 DOI: 10.1182/Blood-2011-11-394346 |
0.358 |
|
| 2012 |
Nyland SB, Krissinger DJ, Clemente MJ, Irby RB, Baab KT, Jarbadan NR, Sokol L, Schaefer E, Liao J, Cuthbertson D, Epling-Burnette P, Paquette R, List AF, Maciejewski JP, Loughran TP. Seroreactivity to LGL leukemia-specific epitopes in aplastic anemia, myelodysplastic syndrome and paroxysmal nocturnal hemoglobinuria: results of a bone marrow failure consortium study. Leukemia Research. 36: 581-7. PMID 22386729 DOI: 10.1016/J.Leukres.2012.02.001 |
0.398 |
|
| 2012 |
McDaniel JM, Zou JX, Fulp W, Chen DT, List AF, Epling-Burnette PK. Reversal of T-cell tolerance in myelodysplastic syndrome through lenalidomide immune modulation. Leukemia. 26: 1425-9. PMID 22193963 DOI: 10.1038/Leu.2011.359 |
0.692 |
|
| 2012 |
Bai F, Villagra AV, Zou J, Painter JS, Connolly K, Blaskovich MA, Sokol L, Sebti S, Djeu JY, Loughran TP, Wei S, Sotomayor E, Epling-Burnette P. Tipifarnib-mediated suppression of T-bet-dependent signaling pathways. Cancer Immunology, Immunotherapy : Cii. 61: 523-33. PMID 21983879 DOI: 10.1007/S00262-011-1109-0 |
0.42 |
|
| 2012 |
Mailloux AW, List AF, Epling-Burnette PK. Response to comment on "expansion of effector memory regulatory T cells represents a novel prognostic factor in lower risk myelodysplastic syndrome" Journal of Immunology. 189: 4199-4200. DOI: 10.4049/Jimmunol.1290064 |
0.385 |
|
| 2012 |
Komrokji RS, Ali NHA, Mishra A, Corrales-Yepez M, Padron E, Zhang L, Epling-Burnette PK, Little BJ, Pinilla-Ibarz J, Lancet JE, List AF. The Utility of New Prognostic Models in Lower Risk MDS to Identify Patients Who Drive Survival Advantage From Disease Altering Treatment Modalities Blood. 120: 3852-3852. DOI: 10.1182/Blood.V120.21.3852.3852 |
0.314 |
|
| 2012 |
Padron E, Ali NHA, Peker D, Lancet JE, Epling-Burnette PK, Zhang L, List AF, Komrokji RS. Hypomethylating Agents Improve Overall Survival in Higher Risk Chronic Myelomonocytic Leukemia (CMML) Blood. 120: 3838-3838. DOI: 10.1182/Blood.V120.21.3838.3838 |
0.322 |
|
| 2012 |
Komrokji RS, Corrales-Yepez M, Al Ali NH, Padron E, Zhang L, Epling-Burnette PK, Pinilla-Ibarz J, Lancet JE, List AF. Validation of the Lower Risk MD Anderson Prognostic Scoring System for Patients with Myelodysplastic Syndromes Blood. 120: 3826-3826. DOI: 10.1182/Blood.V120.21.3826.3826 |
0.334 |
|
| 2012 |
Padron E, Painter JS, Mailloux AW, McGraw KL, McDaniel JM, Bebbington C, Baer M, Yarranton G, Lancet JE, Komrokji RS, List AF, Epling-Burnette P. Preclinical Characterization of KB003, a Novel Humaneered™ Monoclonal Anti-GM-CSF Antibody, Demonstrates That the GM-CSF Signaling Axis Is a Therapeutic Target in Chronic Myelomonocytic Leukemia (CMML) Blood. 120: 3793-3793. DOI: 10.1182/Blood.V120.21.3793.3793 |
0.717 |
|
| 2012 |
Peker D, Padron E, Horna P, Bennett JM, Zhang X, Epling-Burnette PK, Lancet JE, Pinilla J, Moscinski L, List AF, Komrokji RS, Zhang L. A Close Association of History of Autoimmunity with Chronic Myelomonocytic Leukemia (CMML) in Contrast to Chronic Myelogenous Leukemia (CML) Blood. 120: 1712-1712. DOI: 10.1182/Blood.V120.21.1712.1712 |
0.353 |
|
| 2012 |
Padron E, Ali NHA, Peker D, Lancet JE, Epling-Burnette PK, Zhang L, List AF, Komrokji RS. A Comparison of Prognostic Models for Chronic Myelomonocytic Leukemia (CMML) in the Era of Hypomethylating Agents Blood. 120: 1695-1695. DOI: 10.1182/Blood.V120.21.1695.1695 |
0.314 |
|
| 2012 |
Mailloux AW, Sugimori C, Komrokji RS, Maciejewski JP, Sekeres MA, Paquette R, Loughran TP, List AF, Epling-Burnette PK. Abstract 5417: Expansion of effector regulatory T-cells represents a novel and independent prognostic factor marking escape from immune surveillance in Myleodysplastic Syndrome Cancer Research. 72: 5417-5417. DOI: 10.1158/1538-7445.Am2012-5417 |
0.451 |
|
| 2011 |
Rollison DE, Epling-Burnette PK, Park JY, Lee JH, Park H, Jonathan K, Cole AL, Painter JS, Guerrier M, Meléndez-Santiago J, Fulp W, Komrokji R, Lancet J, List AF. Telomere length in myelodysplastic syndromes. Leukemia & Lymphoma. 52: 1528-36. PMID 21635204 DOI: 10.3109/10428194.2011.568648 |
0.388 |
|
| 2011 |
Powers JJ, Dubovsky JA, Epling-Burnette PK, Moscinski L, Zhang L, Mustjoki S, Sotomayor EM, Pinilla-Ibarz JA. A molecular and functional analysis of large granular lymphocyte expansions in patients with chronic myelogenous leukemia treated with tyrosine kinase inhibitors. Leukemia & Lymphoma. 52: 668-79. PMID 21271862 DOI: 10.3109/10428194.2010.550074 |
0.414 |
|
| 2011 |
Mailloux AW, Zhang L, Yang L, Wei C, Sokol L, Moscinski L, Bennett JM, Loughran TP, Epling-Burnette PK. Cytopenias in Large Granular Lymphocyte Leukemia Are Mediated by Pro-Fibrotic Mesenchymal Stem Cells in the Bone Marrow Niche with Functional Restoration by FGFb Blood. 118: 932-932. DOI: 10.1182/Blood.V118.21.932.932 |
0.395 |
|
| 2011 |
Yang L, Mailloux AW, Rollison DE, Park J, Painter JS, Komrokji RS, Maciejewski JP, Paquette R, Loughran TP, Wei S, List AF, Epling-Burnette PK. Human Telomerase Reverse Transcriptase (hTERT) Deficiency in Myelodysplastic Syndrome (MDS) Demonstrates Mechanistic Linkage to Aplastic Anemia Pathophysiology Blood. 118: 791-791. DOI: 10.1182/Blood.V118.21.791.791 |
0.492 |
|
| 2011 |
Wei S, Chen X, Zhou J, Zhang L, Fortenbery NR, Rasche SS, McGraw K, Eksioglu EA, Epling-Burnette P, Djeu JY, Gabrilovich DI, List AF. Microenvironment Induced Myelodysplastic Syndrome (MDS) in S100A9 Transgenic Mice Caused by Myeloid-Derived Suppressor Cells (MDSC) Blood. 118: 788-788. DOI: 10.1182/Blood.V118.21.788.788 |
0.392 |
|
| 2011 |
Komrokji RS, Ali NHA, Corrales-Yepez M, Padron E, Epling-Burnette PK, Lancet JE, List AF. Impact of Iron Overload in Higher Risk Myelodysplastic Syndromes Blood. 118: 2777-2777. DOI: 10.1182/Blood.V118.21.2777.2777 |
0.323 |
|
| 2011 |
Painter JS, Park J, Clemente MJ, O'Keefe CL, Wei S, Maciejewski JP, Paquette R, Loughran TP, List AF, Epling-Burnette PK. Increased Group B Killer Cell Immunoglobulin-Like Receptor (KIR) Haplotypes with Mismatched MHC Class I and Altered NK Repertoire Distribution in Bone Marrow Failure Syndromes Blood. 118: 2412-2412. DOI: 10.1182/Blood.V118.21.2412.2412 |
0.428 |
|
| 2011 |
Powers J, Padron E, Dubovsky J, Berchmans E, Farnum T, Bai F, Sahakian E, Ahmed J, Komrokji RS, Lancet JE, List AF, McNeel DG, Dessureault S, Antonia S, Sotomayor EM, ... Epling-Burnette P, et al. Enhanced Immunological Responses Following K562/GM-CSF/CD40L Vaccine Plus Lenalidomide in High-Risk Myelodysplastic Syndrome Blood. 118: 1725-1725. DOI: 10.1182/Blood.V118.21.1725.1725 |
0.355 |
|
| 2011 |
Padron E, Painter JS, Mailloux AW, McDaniel JM, Bebbington C, Baer M, Komrokji RS, List AF, Epling-Burnette PK. GM-CSF Signaling Abnormalities in Chronic Myelomonocytic Leukemia Blood. 118: 1713-1713. DOI: 10.1182/Blood.V118.21.1713.1713 |
0.706 |
|
| 2011 |
Mailloux AW, Sugimori C, Komrokji RS, Maciejewski JP, Paquette R, Loughran TP, List AF, Epling-Burnette PK. A Switch in Regulatory T-Cell Memory Phenotype Is Associated with Poor Survival in Lower Risk Myleodysplastic Syndrome Patients Blood. 118: 1703-1703. DOI: 10.1182/Blood.V118.21.1703.1703 |
0.482 |
|
| 2011 |
McDaniel JM, Zou J, List AF, Epling-Burnette PK. CD8+ CD28null T Cell Expansion Impairs Lenalidomide Immunomodulatory Function in Myelodysplastic Syndrome Blood. 118: 1117-1117. DOI: 10.1182/Blood.V118.21.1117.1117 |
0.745 |
|
| 2011 |
Zhang L, Zou J, Fulp J, Chen D-, Bai F, Painter JS, Wei S, Komrokji R, List A, Epling-Burnette PK. 54 Terminal effector memory T cell expansion: Biomarker for lenalidomide resistance in myelodysplastic syndrome Leukemia Research. 35. DOI: 10.1016/S0145-2126(11)70056-X |
0.34 |
|
| 2010 |
Sugimori C, List AF, Epling-Burnette PK. Immune dysregulation in myelodysplastic syndrome. Hematology Reports. 2: e1. PMID 22184512 DOI: 10.4081/Hr.2010.E1 |
0.43 |
|
| 2010 |
Epling-Burnette PK, Loughran TP. Suppression of farnesyltransferase activity in acute myeloid leukemia and myelodysplastic syndrome: current understanding and recommended use of tipifarnib. Expert Opinion On Investigational Drugs. 19: 689-98. PMID 20402600 DOI: 10.1517/13543781003801076 |
0.322 |
|
| 2010 |
McGraw KR, Zhang LM, Rollison DE, Lin H, Rawal B, Billingsley D, Kurtin SE, Caceres G, Clark J, Sokol L, Epling-Burnette PK, Guinta K, Maciejewski JP, Mallo M, Solé F, et al. Predisposition to Myelodysplastic Syndrome with Deletion 5q Is Associated with TP53 Codon 72 Genotype Blood. 116: 612-612. DOI: 10.1182/Blood.V116.21.612.612 |
0.324 |
|
| 2010 |
Epling-Burnette P, Komrokji RS, Maciejewski JP, Sekeres MA, Paquette R, Wei S, Painter JS, Bai F, Fulp WJ, Paleveda-Pena J, Chen D, List AF. Phase 2 Multicenter Trial of Rabbit Anti-Thymocyte Serotherapy In Myelodysplastic Syndrome: Rate of Hematological Improvement Associated with Pre-Treatment Disease Duration Blood. 116: 602-602. DOI: 10.1182/Blood.V116.21.602.602 |
0.39 |
|
| 2010 |
Corrales-Yepez M, Kharfan-Dabaja MA, Lancet J, List AF, Padron E, Rollison D, Epling-Burnette P, Zhang L, Field T, Pinilla-Ibarz J, Komrokji RS. Hypoalbuminemia Is An Independent Prognostic Factor In Myelodysplastic Syndromes Blood. 116: 4001-4001. DOI: 10.1182/Blood.V116.21.4001.4001 |
0.316 |
|
| 2010 |
Yang L, Schmidt A, Komrokji R, Painter JS, Cole A, List AF, Rollison DE, Epling-Burnette PK. Importance of T-Cell Proliferative Stress In Myelodysplastic Syndrome Blood. 116: 2939-2939. DOI: 10.1182/Blood.V116.21.2939.2939 |
0.475 |
|
| 2010 |
Padron E, Komrokji RS, Lancet JE, List AF, Dessureault S, Antonia S, Ahmed J, Patel S, Powers J, Bai F, Sotomayor EM, Epling-Burnette P, Pinilla-Ibarz J. A Phase I Pilot Study of Bystander Vaccine and Lenalidomide Immune Augmentation In Patients with Myelodysplastic Syndrome (MDS) Blood. 116: 2925-2925. DOI: 10.1182/Blood.V116.21.2925.2925 |
0.385 |
|
| 2010 |
McDaniel JM, Daniel KG, Luhder F, Wei S, Tanner R, Grams D, List AF, Epling-Burnette PK. Virtual and Physical Analysis of the Proximal T Cell Signalosome Reveals PP2A Inhibition Is Important for Co-Stimulatory Function of Immunomodulatory (IMiD) Drugs Blood. 116: 281-281. DOI: 10.1182/Blood.V116.21.281.281 |
0.712 |
|
| 2010 |
Mailloux AW, Bai F, Zhang L, Padron E, Yang L, Wei C, Schmidt A, Sokol L, Chen D, Loughran TP, List AF, Epling-Burnette PK. Altered Collagen Production by Dysfunctional Mesenchymal Stem Cells Is Linked to T Cell Large Granular Lymphocyte Leukemia Pathophysiology. Blood. 116: 2595-2595. DOI: 10.1182/Blood.V116.21.2595.2595 |
0.429 |
|
| 2010 |
Nyland SB, Krissinger DJ, Clemente M, Irby RB, Baab KT, Jarbadan NR, Sokol L, Schaefer E, Liao J, Cuthbertson D, Epling-Burnette P, Paquette R, Maciejewski JP, Loughran TP. HTLV-1 Epitope (BA21) Reactivity in Rare Bone Marrow Failure Diseases Blood. 116: 1724-1724. DOI: 10.1182/Blood.V116.21.1724.1724 |
0.39 |
|
| 2010 |
Zou J, Painter JS, Bai F, Sokol L, Loughran TP, Epling-Burnette PK. Autoproliferation Contributes to Clonal Expansion and Changes In Cellular Topography In T Cell Large Granular Lymphocyte (LGL) Leukemia Blood. 116: 1373-1373. DOI: 10.1182/Blood.V116.21.1373.1373 |
0.453 |
|
| 2010 |
Epling-Burnette PK, Wei S, Djeu JY. Signalling events in natural killer cells Natural Killer Cells. 95-112. DOI: 10.1016/B978-0-12-370454-2.00007-7 |
0.304 |
|
| 2009 |
Wei S, Chen X, Rocha K, Epling-Burnette PK, Djeu JY, Liu Q, Byrd J, Sokol L, Lawrence N, Pireddu R, Dewald G, Williams A, Maciejewski J, List A. A critical role for phosphatase haplodeficiency in the selective suppression of deletion 5q MDS by lenalidomide. Proceedings of the National Academy of Sciences of the United States of America. 106: 12974-9. PMID 19470455 DOI: 10.1073/Pnas.0811267106 |
0.336 |
|
| 2009 |
Epling-Burnette PK, List AF. Advancements in the molecular pathogenesis of myelodysplastic syndrome. Current Opinion in Hematology. 16: 70-6. PMID 19468267 DOI: 10.1097/Moh.0B013E3283257Ac7 |
0.324 |
|
| 2009 |
Mustjoki S, Ekblom M, Arstila TP, Dybedal I, Epling-Burnette PK, Guilhot F, Hjorth-Hansen H, Höglund M, Kovanen P, Laurinolli T, Liesveld J, Paquette R, Pinilla-Ibarz J, Rauhala A, Shah N, et al. Clonal expansion of T/NK-cells during tyrosine kinase inhibitor dasatinib therapy. Leukemia. 23: 1398-405. PMID 19295545 DOI: 10.1038/Leu.2009.46 |
0.436 |
|
| 2009 |
Zou JX, Rollison DE, Boulware D, Chen DT, Sloand EM, Pfannes LV, Goronzy JJ, Bai F, Painter JS, Wei S, Cosgrove D, List AF, Epling-Burnette PK. Altered naive and memory CD4+ T-cell homeostasis and immunosenescence characterize younger patients with myelodysplastic syndrome. Leukemia. 23: 1288-96. PMID 19282834 DOI: 10.1038/leu.2009.14 |
0.375 |
|
| 2009 |
Chen X, Bai F, Sokol L, Zhou J, Ren A, Painter JS, Liu J, Sallman DA, Chen YA, Yoder JA, Djeu JY, Loughran TP, Epling-Burnette PK, Wei S. A critical role for DAP10 and DAP12 in CD8+ T cell-mediated tissue damage in large granular lymphocyte leukemia. Blood. 113: 3226-34. PMID 19075187 DOI: 10.1182/Blood-2008-07-168245 |
0.484 |
|
| 2009 |
Wei S, Chen X, Rocha K, Qi D, Tao J, Gjertsen N, Zhou J, Liu J, Gabrilovich D, Epling-Burnette PK, Djeu JY, List AF. Myeloid-Derived Suppressor Cells (MDSC) Are Effectors of Bone Marrow Suppression in Lower Risk Myelodysplastic Syndromes (MDS). Blood. 114: 597-597. DOI: 10.1182/Blood.V114.22.597.597 |
0.386 |
|
| 2009 |
Sugimori C, Shain KH, Caceres G, Sokol L, Araten D, Maciejewski JP, Zou J, Epling-Burnette PK, List AF. Co-Existance of JAK V617F and PIG-A mutations in Primary Budd-Chiari Syndrome. Blood. 114: 3193-3193. DOI: 10.1182/Blood.V114.22.3193.3193 |
0.389 |
|
| 2009 |
Epling-Burnette PK, List AF, Clark J, Lee J, Jonathan KA, Fulp W, Li X, Zheng W, Painter JS, Zou J, Komrokji RS, Wei S, Park J, Schmidt A, Sugimori C, et al. Pathogenetic Role of Impaired Telomere Repair in Myelodysplastic Syndrome. Blood. 114: 2777-2777. DOI: 10.1182/Blood.V114.22.2777.2777 |
0.415 |
|
| 2009 |
Powers JJ, Dubovsky JA, Zhang L, Moscinski LC, Epling-Burnette P, Sotomayor EM, Pinilla J. Molecular and Functional Analysis of Large Granular Lymphocyte Expansions in Chronic Myelogenous Leukemia Patients Undergoing Tyrosine Kinase Inhibitor Therapy. Blood. 114: 2204-2204. DOI: 10.1182/Blood.V114.22.2204.2204 |
0.475 |
|
| 2009 |
Epling-Burnette P, Zou J, Painter JS, Chen D, Fulp J, Komrokji RS, Wei S, List AF. Functional T Cell Array Reveals Pre-Treatment Expanded Terminal Effector Memory Response Is Associated with Lenalidomide Failure in Non-Del(5q) Myelodysplastic Syndrome. Blood. 114: 1759-1759. DOI: 10.1182/Blood.V114.22.1759.1759 |
0.498 |
|
| 2009 |
Schmidt A, Komrokji RS, Painter JS, Rollison DE, Zhang L, Moscinski LC, List AF, Epling-Burnette PK. Positive Impact of T-Cell Clonal Expansion On Overall Survival in Patients with High-Risk Myelodysplastic Syndromes. Blood. 114: 1572-1572. DOI: 10.1182/Blood.V114.22.1572.1572 |
0.457 |
|
| 2009 |
List AF, Epling-Burnette PK, Zou JX, Bai F, Painter JS, Wei S, Sugimori C. 4 Controlling the "fate" of T cells in MDS Leukemia Research. 33. DOI: 10.1016/S0145-2126(09)70004-9 |
0.376 |
|
| 2008 |
Epling-Burnette PK, Sokol L, Chen X, Bai F, Zhou J, Blaskovich MA, Zou J, Painter JS, Edwards TD, Moscinski L, Yoder JA, Djeu JY, Sebti S, Loughran TP, Wei S. Clinical improvement by farnesyltransferase inhibition in NK large granular lymphocyte leukemia associated with imbalanced NK receptor signaling. Blood. 112: 4694-8. PMID 18791165 DOI: 10.1182/Blood-2008-02-136382 |
0.341 |
|
| 2008 |
Yang J, Epling-Burnette PK, Painter JS, Zou J, Bai F, Wei S, Loughran TP. Antigen activation and impaired Fas-induced death-inducing signaling complex formation in T-large-granular lymphocyte leukemia. Blood. 111: 1610-6. PMID 17993614 DOI: 10.1182/Blood-2007-06-093823 |
0.417 |
|
| 2008 |
Lai DW, Loughran TP, Maciejewski JP, Sasu S, Song SX, Epling-Burnette PK, Paquette RL. Acquired amegakaryocytic thrombocytopenia and pure red cell aplasia associated with an occult large granular lymphocyte leukemia. Leukemia Research. 32: 823-7. PMID 17915315 DOI: 10.1016/J.Leukres.2007.08.012 |
0.372 |
|
| 2008 |
Bourgault-Rouxel AS, Loughran TP, Zambello R, Epling-Burnette PK, Semenzato G, Donadieu J, Amiot L, Fest T, Lamy T. Clinical spectrum of gammadelta+ T cell LGL leukemia: analysis of 20 cases. Leukemia Research. 32: 45-8. PMID 17544120 DOI: 10.1016/J.Leukres.2007.04.011 |
0.476 |
|
| 2008 |
Epling-Burnette PK, Painter JS, Lee H-, Park J, Clemente M, O’Keefe C, Wei T, Wei S, Maciejewski J, Loughran TP, Paquette R, List AF, Djeu JY. Genetic Disparities in Killer Cell Immunoglobulin-Like Receptors (KIR) and MHC Class I in Bone Marrow Failure Syndromes Blood. 112: 4121-4121. DOI: 10.1182/Blood.V112.11.4121.4121 |
0.487 |
|
| 2008 |
Clemente M, Cazzolli H, Jankowska A, O’Keefe C, Serio B, Nyland S, Wlodarski M, Epling-Burnette P, Loughran T, List A, Paquette R, Maciejewski J. Permissive Conditions for Evolution of PNH Clones Are Characterized by Overproduction of IFN-γ by Clonal CD4 and CD8 T Cells, Fas-L by CTLs, and Promoted by Immunogenetic Background Blood. 112: 4116-4116. DOI: 10.1182/Blood.V112.11.4116.4116 |
0.476 |
|
| 2008 |
Rollison DE, List AF, Lee J, Jonathan KA, Fulp W, Li X, Zheng W, Painter J, Park J, Epling-Burnette P. Short Telomere Length as a Risk Factor for Myelodysplastic Syndromes: A Case-Control Study Blood. 112: 2674-2674. DOI: 10.1182/Blood.V112.11.2674.2674 |
0.395 |
|
| 2008 |
Powers JJ, Painter JS, Dubovsky JA, Epling-Burnette P, Pinilla J. A Comprehensive Lymphocyte Analysis of Dasatinib Treated Chronic Myelogenous Leukemia Patients Reveals T-Cell Oligoclonality. Blood. 112: 1114-1114. DOI: 10.1182/Blood.V112.11.1114.1114 |
0.464 |
|
| 2007 |
Epling-Burnette PK, Bai F, Painter JS, Rollison DE, Salih HR, Krusch M, Zou J, Ku E, Zhong B, Boulware D, Moscinski L, Wei S, Djeu JY, List AF. Reduced natural killer (NK) function associated with high-risk myelodysplastic syndrome (MDS) and reduced expression of activating NK receptors. Blood. 109: 4816-24. PMID 17341666 DOI: 10.1182/Blood-2006-07-035519 |
0.4 |
|
| 2007 |
Epling-Burnette PK, Painter JS, Rollison DE, Ku E, Vendron D, Widen R, Boulware D, Zou JX, Bai F, List AF. Prevalence and clinical association of clonal T-cell expansions in Myelodysplastic Syndrome. Leukemia. 21: 659-67. PMID 17301813 DOI: 10.1038/Sj.Leu.2404590 |
0.375 |
|
| 2007 |
Ku E, Alekshun T, Loughran TP, Sokol L, Epling-Burnette PK. Large granular lymphocyte (LGL) leukemia: Pathobiology, diagnosis and treatment Current Cancer Therapy Reviews. 3: 141-150. DOI: 10.2174/157339407780618452 |
0.42 |
|
| 2007 |
Epling-Burnette PK, Chen X, Zhou J, Bai F, Lubomir S, Ku E, Painter JS, JianXiang Z, Edwards TD, Julie DY, Lynn MC, Loughran TP, Wei S. Aberrant NK Receptor Signaling Associated with Large Granular Lymphoycte Leukemia and Primary Pulmonary Hypertension. Blood. 110: 4704-4704. DOI: 10.1182/Blood.V110.11.4704.4704 |
0.43 |
|
| 2007 |
Painter JS, Costellanos A, Bai F, Wei S, Loughran TP, Epling-Burnette PK. Constitutive Activation of Ras and Mitogen-Activated Protein Kinase (MAPK/ERK) in LGL Leukemia Unrelated to Activating Mutations in N and KRas Genes. Blood. 110: 3180-3180. DOI: 10.1182/Blood.V110.11.3180.3180 |
0.398 |
|
| 2007 |
Bai F, Zou J-, Wei S, Painter JS, Blaskovich M, Sebti S, Loughran TP, Epling-Burnette PK. Th2 Polarization Induced by the Farnesyltransferase Inhibitor Tipifarnib (Zarnestra®, R115777) through Suppression of T-bet. Blood. 110: 1331-1331. DOI: 10.1182/Blood.V110.11.1331.1331 |
0.422 |
|
| 2006 |
Zou J, Ku E, Bai F, Painter JS, List AF, Epling-Burnette PK. Lenalidomide (CC5013, Revlimid®) Alters a T Cell Homeostatic Check-Point in Patients with Myelodysplastic Syndrome (MDS). Blood. 108: 851-851. DOI: 10.1182/Blood.V108.11.851.851 |
0.509 |
|
| 2006 |
Zou J, Painter JS, Bai F, Loughran TP, Epling-Burnette PK. T Large Granular Lymphocyte (LGL) Leukemia Characterized by Expansion of Terminal CD3+/CD8+/CD62L−/CD45RA+ Effector Memory T Cells. Blood. 108: 4962-4962. DOI: 10.1182/Blood.V108.11.4962.4962 |
0.467 |
|
| 2006 |
Bai F, Zou J, Yang J, Ku E, Wei S, Loughran TP, Epling-Burnette P. Complex Immunosuppressive Action of Farnesyltransferase Inhibitor (FTI) R115777 (Tipifarnib, Zarnestra®) with Induction of Apoptosis in T Cells from Patients with Large Granular Lymphocyte (LGL) Leukemia. Blood. 108: 4960-4960. DOI: 10.1182/Blood.V108.11.4960.4960 |
0.501 |
|
| 2006 |
Ku E, Zou J, Bai F, Painter JS, List AF, Epling-Burnette PK. Lenalidomide (CC5013, Revlimid®) Promotes T Helper-1 Function Bias and Increases Responsiveness to Autologous Bone Marrow Antigens in Myelodysplastic Syndrome (MDS). Blood. 108: 2659-2659. DOI: 10.1182/Blood.V108.11.2659.2659 |
0.483 |
|
| 2006 |
Epling-Burnette PK, Bai F, Painter JS, Dana R, Zou J, Ku E, Zhong B, Wei S, Djeu JY, List AF. Reduced Natural Killer Function Accompanies MDS Disease Progression and Is Restored by Lenalidomide (CC5013, Revlimid®) Via a Mechanism Divergent from Interleukin-2 (IL-2). Blood. 108: 2651-2651. DOI: 10.1182/Blood.V108.11.2651.2651 |
0.397 |
|
| 2005 |
Epling-Burnette PK, Bai F, Painter JS, Djeu JY, List AF. Lenalidomide Effects on NK Function in Patients with Myelodysplastic Syndrome (MDS). Blood. 106: 3437-3437. DOI: 10.1182/Blood.V106.11.3437.3437 |
0.46 |
|
| 2005 |
Bai F, Painter JS, Alan C, JianXiang Z, Wei S, Djeu JY, List AF, Epling-Burnette PK. Natural Killer Cells with NKDG2D Cytotoxicity but NKp30-Dull Phenotype Predominate in Myelodysplastic Syndrome (MDS). Blood. 106: 3436-3436. DOI: 10.1182/Blood.V106.11.3436.3436 |
0.424 |
|
| 2005 |
Painter JS, Fanqi B, Cantor A, List AF, Epling-Burnette PK. Clonal T Cell Expansion in High Risk Myelodysplastic Syndrome (MDS). Blood. 106: 3435-3435. DOI: 10.1182/Blood.V106.11.3435.3435 |
0.492 |
|
| 2005 |
Epling-Burnette PK, Bai F, Painter JS, Loughran TP. In Addition to Immune Suppression, There Is Defective Maturation of CD34+ Cells in Patients with Natural Killer-Lymphoproliferative Disease of Granular Lymphcoytes (NK-LDGL). Blood. 106: 2404-2404. DOI: 10.1182/Blood.V106.11.2404.2404 |
0.459 |
|
| 2004 |
Epling-Burnette PK, Bai F, Wei S, Chaurasia P, Painter JS, Olashaw N, Hamilton A, Sebti S, Djeu JY, Loughran TP. ERK couples chronic survival of NK cells to constitutively activated Ras in lymphoproliferative disease of granular lymphocytes (LDGL). Oncogene. 23: 9220-9. PMID 15516985 DOI: 10.1038/Sj.Onc.1208122 |
0.405 |
|
| 2004 |
Epling-Burnette PK, Painter JS, Chaurasia P, Bai F, Wei S, Djeu JY, Loughran TP. Dysregulated NK receptor expression in patients with lymphoproliferative disease of granular lymphocytes. Blood. 103: 3431-9. PMID 14726391 DOI: 10.1182/Blood-2003-02-0400 |
0.415 |
|
| 2004 |
Epling-Burnette PK, Painter JS, Bai F, Mohaptra S, Loughran TP. Apoptosis by Low-Dose Methotrexate Occurs in Fully Activated Proliferating CD4+ and CD8+ Lymphocytes and in Leukemic LGL after Mitogenic Stimulation using a FADD-Dependent Pathway. Blood. 104: 2666-2666. DOI: 10.1182/Blood.V104.11.2666.2666 |
0.466 |
|
| 2004 |
Epling-Burnette PK, Bai F, Painter JS, Wei S, Djeu JY, Loughran TP. Reduced Inhibitory KIR Receptors in Patients with NK-Lymphoproliferative Disease of Large Granular Lymphocytes (NK-LDGL) Leads to Dysregulated Killing. Blood. 104: 2661-2661. DOI: 10.1182/Blood.V104.11.2661.2661 |
0.405 |
|
| 2003 |
Epling-Burnette PK, Loughran TP. Survival signals in leukemic large granular lymphocytes. Seminars in Hematology. 40: 213-20. PMID 12876670 DOI: 10.1016/S0037-1963(03)00135-5 |
0.402 |
|
| 2003 |
Zhong B, Jiang K, Gilvary DL, Epling-Burnette PK, Ritchey C, Liu J, Jackson RJ, Hong-Geller E, Wei S. Human neutrophils utilize a Rac/Cdc42-dependent MAPK pathway to direct intracellular granule mobilization toward ingested microbial pathogens. Blood. 101: 3240-8. PMID 12511425 DOI: 10.1182/Blood-2001-12-0180 |
0.319 |
|
| 2003 |
Kothapalli R, Bailey RD, Kusmartseva I, Mane S, Epling-Burnette PK, Loughran TP. Constitutive expression of cytotoxic proteases and down-regulation of protease inhibitors in LGL leukemia. International Journal of Oncology. 22: 33-9. PMID 12469182 DOI: 10.3892/Ijo.22.1.33 |
0.354 |
|
| 2002 |
Huang M, Dorsey JF, Epling-Burnette PK, Nimmanapalli R, Landowski TH, Mora LB, Niu G, Sinibaldi D, Bai F, Kraker A, Yu H, Moscinski L, Wei S, Djeu J, Dalton WS, et al. Inhibition of Bcr-Abl kinase activity by PD180970 blocks constitutive activation of Stat5 and growth of CML cells. Oncogene. 21: 8804-16. PMID 12483533 DOI: 10.1038/Sj.Onc.1206028 |
0.349 |
|
| 2002 |
Epling-Burnette PK, Garcia R, Bai F, Ismail S, Loughran TP, Djeu JY, Jove R, Wei S. Carboxy-terminal truncated STAT5 is induced by interleukin-2 and GM-CSF in human neutrophils. Cellular Immunology. 217: 1-11. PMID 12425996 DOI: 10.1016/S0008-8749(02)00522-1 |
0.312 |
|
| 2002 |
Liu JH, Wei S, Lamy T, Li Y, Epling-Burnette PK, Djeu JY, Loughran TP. Blockade of Fas-dependent apoptosis by soluble Fas in LGL leukemia. Blood. 100: 1449-53. PMID 12149230 DOI: 10.1182/Blood.V100.4.1449.H81602001449_1449_1453 |
0.343 |
|
| 2001 |
Epling-Burnette PK, Zhong B, Bai F, Jiang K, Bailey RD, Garcia R, Jove R, Djeu JY, Loughran TP, Wei S. Cooperative regulation of Mcl-1 by Janus kinase/stat and phosphatidylinositol 3-kinase contribute to granulocyte-macrophage colony-stimulating factor-delayed apoptosis in human neutrophils. Journal of Immunology (Baltimore, Md. : 1950). 166: 7486-95. PMID 11390502 DOI: 10.4049/Jimmunol.166.12.7486 |
0.325 |
|
| 2001 |
Epling-Burnette PK, Liu JH, Catlett-Falcone R, Turkson J, Oshiro M, Kothapalli R, Li Y, Wang JM, Yang-Yen HF, Karras J, Jove R, Loughran TP. Inhibition of STAT3 signaling leads to apoptosis of leukemic large granular lymphocytes and decreased Mcl-1 expression. The Journal of Clinical Investigation. 107: 351-62. PMID 11160159 DOI: 10.1172/Jci9940 |
0.37 |
|
| 2000 |
Liu JH, Wei S, Lamy T, Epling-Burnette PK, Starkebaum G, Djeu JY, Loughran TP. Chronic neutropenia mediated by fas ligand. Blood. 95: 3219-22. PMID 10807792 DOI: 10.1182/Blood.V95.10.3219.010K33_3219_3222 |
0.306 |
|
| 2000 |
Epling-Burnette P, Catlett-Falcone R, Kothapalli R, Oshiro M, Jove R, Loughran T. Induction of apoptosis in large granular lymphocyte (Lgl) Leukemia by jak tyrosine kinase inhibitor AG-490 Experimental Hematology. 28: 90-91. DOI: 10.1016/S0301-472X(00)00369-6 |
0.354 |
|
| 1997 |
Pericle F, Epling-Burnette PK, Podack ER, Wei S, Djeu JY. CD40-CD40L interactions provide "third-party" costimulation for T cell response against B7-1-transfected human breast tumor cells. Journal of Leukocyte Biology. 61: 201-8. PMID 9021926 DOI: 10.1002/Jlb.61.2.201 |
0.444 |
|
| 1996 |
Pericle F, Kirken RA, Epling-Burnette PK, Blanchard DK, Djeu JY. Direct killing of interleukin-2-transfected tumor cells by human neutrophils. International Journal of Cancer. Journal International Du Cancer. 66: 367-73. PMID 8621259 DOI: 10.1002/(Sici)1097-0215(19960503)66:3<367::Aid-Ijc17>3.0.Co;2-8 |
0.328 |
|
| 1993 |
Epling-Burnette PK, Wei S, Blanchard DK, Spranzi E, Djeu JY. Coinduction of granulocyte-macrophage colony-stimulating factor release and lymphokine-activated killer cell susceptibility in monocytes by interleukin-2 via interleukin-2 receptor beta. Blood. 81: 3130-7. PMID 8499646 DOI: 10.1182/Blood.V81.11.3130.Bloodjournal81113130 |
0.314 |
|
| 1993 |
Spranzi E, Djeu JY, Hoffman SL, Epling-Burnette PK, Blanchard DK. Lysis of human monocytic leukemia cells by extracellular adenosine triphosphate: mechanism and characterization of the adenosine triphosphate receptor. Blood. 82: 1578-85. PMID 8364207 DOI: 10.1182/Blood.V82.5.1578.Bloodjournal8251578 |
0.321 |
|
| Show low-probability matches. |